PURPOSE: There is a limited number of therapies with a high level of recommendations for mucositis, while several strategies are currently employed with a limited evidence for efficacy. A national survey among Italian oncologists who treat head and neck cancer (HNC) was conducted in order to assess the most common preventive and therapeutic protocols (including nutritional support and pain control) for oral mucositis (OM) in patients undergoing chemoradiotherapy. METHODS: From September to November 2012, a nationwide electronic survey with 21 focused items was proposed to chemotherapy and radiotherapy centers. RESULTS: We collected 111 answers. Common Terminology Criteria for Adverse Events (CTCAE) scale is employed by 55% of the physicians in assessing mucosal toxicity. The most relevant predictive factors for OM development are considered smoke, alcohol use, planned radiotherapy, and concurrent use of radiosensitizing chemotherapy. Prophylactic gastrostomy is adopted in <10% of the patients. Preventive antibiotics or antimycotics are prescribed by 46% of the responders (mainly local or systemic antimycotic drugs). Alkalinizing mouthwashes or coating agents are frequently adopted (70% of the cases). Among therapeutic interventions, systemic fluconazole is administered by 80% of the physicians. Pain is mainly treated by weak followed by strong opioids. CONCLUSIONS: A variety of preventive and therapeutic protocols for OM exists among the participating Italian centers, with some uniformity in respect to nutritional support, use of antimycotic and painkillers. There is an urgent need for well-conducted clinical trials aimed at assessing the best choices for OM prevention and treatment in HNC.
PURPOSE: There is a limited number of therapies with a high level of recommendations for mucositis, while several strategies are currently employed with a limited evidence for efficacy. A national survey among Italian oncologists who treat head and neck cancer (HNC) was conducted in order to assess the most common preventive and therapeutic protocols (including nutritional support and pain control) for oral mucositis (OM) in patients undergoing chemoradiotherapy. METHODS: From September to November 2012, a nationwide electronic survey with 21 focused items was proposed to chemotherapy and radiotherapy centers. RESULTS: We collected 111 answers. Common Terminology Criteria for Adverse Events (CTCAE) scale is employed by 55% of the physicians in assessing mucosal toxicity. The most relevant predictive factors for OM development are considered smoke, alcohol use, planned radiotherapy, and concurrent use of radiosensitizing chemotherapy. Prophylactic gastrostomy is adopted in <10% of the patients. Preventive antibiotics or antimycotics are prescribed by 46% of the responders (mainly local or systemic antimycotic drugs). Alkalinizing mouthwashes or coating agents are frequently adopted (70% of the cases). Among therapeutic interventions, systemic fluconazole is administered by 80% of the physicians. Pain is mainly treated by weak followed by strong opioids. CONCLUSIONS: A variety of preventive and therapeutic protocols for OM exists among the participating Italian centers, with some uniformity in respect to nutritional support, use of antimycotic and painkillers. There is an urgent need for well-conducted clinical trials aimed at assessing the best choices for OM prevention and treatment in HNC.
Authors: Giuseppe Sanguineti; Maria Pia Sormani; Shanthi Marur; G Brandon Gunn; Nikhil Rao; Marco Cianchetti; Francesco Ricchetti; Todd McNutt; Binbin Wu; Arlene Forastiere Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Harriët Jager-Wittenaar; Pieter U Dijkstra; Arjan Vissink; Bernard F A M van der Laan; Rob P van Oort; Jan L N Roodenburg Journal: Head Neck Date: 2010-09-07 Impact factor: 3.147
Authors: Paul A Mann; Paul M McNicholas; Andrew S Chau; Reena Patel; Cara Mendrick; Andrew J Ullmann; Oliver A Cornely; Hernando Patino; Todd A Black Journal: Antimicrob Agents Chemother Date: 2009-09-28 Impact factor: 5.191
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Martee L Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; Gary I Cohen; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel von Hoff; Lynn M Schuchter Journal: J Clin Oncol Date: 2008-11-17 Impact factor: 44.544
Authors: Letícia de Freitas Cuba; Aroldo Braga Filho; Karen Cherubini; Fernanda Gonçalves Salum; Maria Antonia Zancanaro de Figueiredo Journal: Support Care Cancer Date: 2015-12-23 Impact factor: 3.603
Authors: Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe Journal: Curr Oncol Rep Date: 2015-11 Impact factor: 5.075
Authors: Jeevendra Kanagalingam; Mohamed Ibrahim A Wahid; Jin-Ching Lin; Nonette A Cupino; Edward Liu; Jin-Hyoung Kang; Shouki Bazarbashi; Nicole Bender Moreira; Harsha Arumugam; Stefan Mueller; Hanlim Moon Journal: Support Care Cancer Date: 2018-01-31 Impact factor: 3.603
Authors: Marwa Al Barmawi; Lourance A Al Hadid; Hani Nawaf Alqudah; Wasfi A Al Hadid; Shaimaa A Shamoun Journal: Asia Pac J Oncol Nurs Date: 2018 Jul-Sep
Authors: Núbia de Cassia Almeida Queiroz; Michelle Pedroza Jorge; Ilza Maria de Oliveira Sousa; Carmen Silvia Passos Lima; Maria Christina de Miranda Matias; Ana Cristina Dal Rio; Eduardo Baldon Pereira; Victória Hahn Kakas Galassi; João Ernesto de Carvalho; Tais Freire Galvao; Mary Ann Foglio Journal: BMJ Open Date: 2018-10-18 Impact factor: 2.692